Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04838652 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma

Study acronym: Pembro-CORE
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 23, 2024 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary completion date: Dec 2024 to May 2026
    • Start date changed from estimate of Dec 2022 to Mar 5, 2024
    • Study completion date: Dec 2026 to May 2028
    • Site details revised
  2. Primary completion date: Dec 2023 to Dec 2024
    • Start date: Jul 2021 to Dec 2022
    • Study completion date: Jul 2025 to Dec 2026
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this trial is to develop an effective and well-tolerated regimen for treatment of r/r cHL by introducing the anti-PD-1 antibody pembrolizumab and adding it to well-established chemotherapy regimens (ICE, DHAP). Synergistic effects of conventional agents with checkpoint inhibition may facilitate a highly effective therapy with limited toxicity, which might eventually substitute the very toxic high-dose chemotherapy (HDCT).
Trial Details
NCT Number NCT04838652
Lead Sponsor University of Cologne
Conditions
(from sponsor)		 Classical Hodgkin Lymphoma
Enrollment 29 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov